Stem Cell Research is a premier Open Access journal published by ELSEVIER, dedicated to advancing the understanding of stem cell biology. Since its inception in 2007, the journal has provided a platform for the latest research in the fields of Cell Biology, Developmental Biology, and Medicine, with its publication being accessible globally since 2014. Located in the Netherlands, the journal’s comprehensive scope aims to bridge fundamental discoveries with clinical applications, fostering collaboration among researchers and professionals. With a 2023 impact factor reflected in its Q4 ranking in Cell and Developmental Biology and a commendable position in the 64th percentile for General Medicine, Stem Cell Research remains a vital resource for those interested in the dynamic landscape of regenerative medicine. Targeting an audience that includes researchers, practitioners, and students, the journal emphasizes not only the significance of stem cells in medical science but also the ethical considerations and the public discourse surrounding stem cell research. Join the community committed to pioneering the future of stem cell science through rigorous peer-reviewed research.

IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL, published by SPRINGER, is a pivotal journal in the fields of cell biology and developmental biology, focusing on in vitro studies that enhance our understanding of animal cellular mechanisms and development. With an ISSN of 1071-2690 and an E-ISSN of 1543-706X, this esteemed journal offers a platform for researchers to present their findings and contribute to the body of knowledge necessary for advancements in biological sciences. As a recognized publication, it holds a 2023 category quartile of Q4 in Cell Biology and Developmental Biology, and Q3 in miscellaneous Medicine, reflecting its competitive position yet inviting critical submissions that can span multidisciplinary approaches. Though currently not open access, it serves as an essential resource for professionals, researchers, and students dedicated to unraveling the complexities of cellular processes in an ever-evolving field. The journal has been continuously published since 1986, signifying its long-standing commitment to fostering scientific discourse and innovation.

Cellular Reprogramming is a prominent academic journal published by MARY ANN LIEBERT, INC, dedicated to advancing the field of cellular biology and biotechnology. With its ISSN 2152-4971 and E-ISSN 2152-4998, this journal provides an innovative platform for researchers and professionals to share groundbreaking research findings on cellular reprogramming, stem cell biology, and regenerative medicine. Established in 2010, and actively publishing until 2024, the journal is recognized for its contributions, evidenced by its categorizations in the Q3 and Q4 quartiles across several related fields, including biotechnology and developmental biology. This peer-reviewed journal not only supports open access to scientific literature but also aims to enhance interdisciplinary collaboration among scientists. With a growing impact in the realms of biochemistry, genetics, and molecular biology, Cellular Reprogramming remains an essential resource for the dissemination of pioneering research that could shape the future of cellular therapies.

American Journal of Stem Cells is a leading multidisciplinary publication dedicated to advancing the field of regenerative medicine and stem cell research. Published by E-CENTURY PUBLISHING CORP, this journal has gained recognition for its commitment to high-quality scientific contributions, achieving impressive rankings within the Scopus database, particularly in the areas of Biochemistry, Genetics and Molecular Biology, and Developmental Biology. With its focus on innovative research, the journal offers crucial insights and developments that appeal to researchers, professionals, and students alike. Although it is not an open-access journal, the American Journal of Stem Cells plays a pivotal role in disseminating impactful findings that define the future of cellular therapies and regenerative methodologies. The journal's past coverage from 2012 to 2017 reflects its dedication to advancing knowledge in key scientific disciplines, making it an essential resource for anyone engaged in the dynamic landscape of stem cell science.

Tissue Engineering Part A is a prestigious peer-reviewed journal published by MARY ANN LIEBERT, INC that focuses on innovative research and advancements within the field of tissue engineering and regenerative medicine. Since its inception in 2008, this journal has played a critical role in disseminating cutting-edge findings that bridge the gap between laboratory research and clinical application, underscoring its significance in the scientific community. With a diverse scope encompassing biochemistry, bioengineering, biomaterials, and biomedical engineering, the journal ranks notably in the Scopus database, holding a Q2 quartile status across multiple categories, thus reflecting its high impact on ongoing research and professional practice. For researchers, professionals, and students, Tissue Engineering Part A serves as an invaluable resource, offering insights into the latest methodologies and breakthroughs that drive the future of healthcare and therapeutic strategies. While primarily a subscription-based journal, it ensures that vital research is accessible to a broad audience of scientists and engineers committed to advancing the life sciences.

Journal of Tissue Engineering and Regenerative Medicine, published by WILEY, stands as a pivotal platform in the fields of biomaterials, biomedical engineering, and regenerative medicine. With an ISSN of 1932-6254 and an E-ISSN of 1932-7005, this journal, based in the United Kingdom, has consistently delivered high-quality research since its inception in 2006, converging critical insights through 2024. With an impressive citation profile reflected in its Scopus rankings—specifically a rank of #58 in Medicine and #75 in Biomedical Engineering—the journal is acknowledged for its substantial impact, as demonstrated by its competitive quartile standings in 2023. Notably, it maintains a Q3 ranking in Biomaterials and Q2 in both Biomedical Engineering and Medicine (miscellaneous), showcasing its influence and relevance in the rapidly evolving interplay between engineering and medicine. The journal serves as a vital resource for researchers and practitioners aiming to stay abreast of innovations and breakthroughs in regenerative therapies, tissue scaffolds, and biomaterials. While not an open-access publication, it fosters academic dialogue and knowledge dissemination that is crucial for advancing the field.

Regenerative Engineering and Translational Medicine is an esteemed academic journal published by Springer Heidelberg, focusing on the interdisciplinary fields of biomaterials, biomedical engineering, and cell biology. With an ISSN of 2364-4133 and an E-ISSN of 2364-4141, the journal has carved a niche for itself since its inception in 2015, showcasing cutting-edge research that bridges the gap between scientific findings and practical applications in regenerative medicine. As a recognized platform in its field, it is currently positioned within Q3 quartiles in biomaterials, biomedical engineering, and medicine (miscellaneous), with a Scopus ranking that reflects its growing influence among peers. The journal aims to disseminate high-quality, peer-reviewed articles that highlight advancements in regenerative engineering, further advancing both theoretical and applied research. Scholars and practitioners seeking to stay at the forefront of the ever-evolving landscape of regenerative health solutions will find invaluable insights and innovations within these pages. Join a community of leading thinkers and explore the journal's comprehensive research contributions, which are crucial for fostering partnerships between academia and industry in the quest for transformative medical solutions.

Stem Cells International is a premier open access journal published by HINDAWI LTD, focusing on the rapidly evolving field of stem cell research. With an ISSN of 1687-966X and E-ISSN 1687-9678, this journal has been a vital resource since its inception in 2010, showcasing innovative studies and breakthroughs up to 2024. Positioned in Q3 in Cell Biology and Q2 in Molecular Biology for 2023, as well as well-ranked in the Scopus database, the journal serves as an essential platform for researchers, professionals, and students dedicated to exploring the implications of stem cell technology in regenerative medicine and biological research. The open access model ensures wide accessibility, fostering collaboration and knowledge-sharing across the scientific community, making it a cornerstone in advancing the understanding and application of stem cell science.

Stem Cells and Cloning-Advances and Applications is a leading peer-reviewed journal dedicated to the dynamic fields of stem cell research and cloning technologies. Published by DOVE MEDICAL PRESS LTD in New Zealand since 2008, this Open Access journal ensures that groundbreaking findings are accessible to a global audience. With a focus on innovative applications and advancements in cellular biology, the journal plays a pivotal role in disseminating knowledge within the scientific community. The journal currently holds an impact factor that reflects its influence, with notable rankings in both Cell Biology and Medicine (Miscellaneous), showcasing its interdisciplinary relevance. Researchers, professionals, and students alike benefit from the journal’s wide-ranging contributions, covering critical topics from regenerative medicine to genetic research. With a commitment to fostering collaboration and encouraging discussion in these cutting-edge domains, Stem Cells and Cloning-Advances and Applications continues to be a vital resource for advancing scientific inquiry and application.

CELL PROLIFERATION, published by Wiley, is a leading open-access journal that has been at the forefront of research since its inception in 1968. With an impact factor that solidifies its position in the Q1 category of both Cell Biology and Medicine (Miscellaneous), this journal serves as a premier platform for disseminating groundbreaking studies in the field of cellular and molecular biology. The journal is renowned for its rigorous peer-review process and comprehensive coverage of topics related to cell growth, division, and differentiation, making it an invaluable resource for researchers, professionals, and students alike. With its notable Scopus ranking of #30 in Biochemistry, Genetics, and Molecular Biology: Cell Biology, and a robust open access model since 2019, CELL PROLIFERATION ensures that cutting-edge research is accessible to a global audience, fostering collaboration and innovation across the scientific community. Located in the United Kingdom, the journal remains committed to enhancing the understanding of cellular processes, thereby influencing developments in medicine and biotechnology.